By David McAfee (March 26, 2014, 7:06 PM EDT) -- A New Jersey federal judge on Wednesday tossed some claims brought against Merck & Co. Inc. in multidistrict litigation accusing the company of negligence over femur fractures and similar injuries allegedly caused by its osteoporosis drug Fosamax, saying those claims are preempted.
Last June, in a related case known as Glynn v. Merck, U.S. District Judge Joel A. Pisano said that claims that Merck had failed to warn a consumer of the possible risk of femur fractures from the use Fosamax were preempted under federal law because the U.S. Food and Drug Administration had refused to strengthen the drug's label the...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!